XML 32 R21.htm IDEA: XBRL DOCUMENT v3.19.1
Disaggregation of Revenues, Geographic Sales and Product Sales
3 Months Ended
Mar. 29, 2019
Segment Reporting [Abstract]  
Disaggregation of Revenues, Geographic Sales and Product Sales

Note 14 — Disaggregation of Revenues, Geographic Sales and Product Sales

In the following tables, revenues are disaggregated by category, sales by geographic market and sales by product data.  The following breaks down revenues into the following categories (in thousands):

 

 

 

Three Months Ended

 

 

 

March 29,

2019

 

 

March 30,

2018

 

Non-consignment sales

 

$

28,266

 

 

$

22,181

 

Consignment sales

 

 

4,317

 

 

 

4,912

 

Total net sales

 

$

32,583

 

 

$

27,093

 

Note 14 — Disaggregation of Revenues, Geographic Sales and Product Sales (Continued)

The Company markets and sells its products in over 75 countries and conducts its manufacturing in the United States.  Other than China, Japan and Korea, the Company does not conduct business in any country in which its sales exceed 10% of worldwide consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers is set forth below (in thousands):

 

 

 

Three Months Ended

 

 

 

March 29,

2019

 

 

March 30,

2018

 

China

 

$

11,771

 

 

$

7,910

 

Japan

 

 

5,519

 

 

 

5,083

 

Korea

 

 

3,291

 

 

 

2,195

 

Other(1)

 

 

12,002

 

 

 

11,905

 

Total net sales

 

$

32,583

 

 

$

27,093

 

 

(1)

No other location individually exceeds 10% of the total sales.

In addition, domestic and foreign sales are as follows (in thousands):

 

 

 

Three Months Ended

 

 

 

March 29,

2019

 

 

March 30,

2018

 

Domestic

 

$

1,952

 

 

$

1,756

 

Foreign

 

 

30,631

 

 

 

25,337

 

Total net sales

 

$

32,583

 

 

$

27,093

 

 

100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery.  The composition of the Company’s net sales by product line is as follows (in thousands):

 

 

 

Three Months Ended

 

 

 

March 29,

2019

 

 

March 30,

2018

 

ICLs

 

$

27,786

 

 

$

21,158

 

Other product sales

 

 

 

 

 

 

 

 

IOLs

 

 

4,017

 

 

 

4,058

 

Other surgical products

 

 

780

 

 

 

1,877

 

Total other product sales

 

 

4,797

 

 

 

5,935

 

Total net sales

 

$

32,583

 

 

$

27,093

 

 

One customer, our distributor in China, accounted for 36% and 29% of net sales for the three months ended March 29, 2019 and March 30, 2018, respectively.  As of March 29, 2019 and December 28, 2018, respectively, one customer, our distributor in China, accounted for 37% and 36% of consolidated trade receivables.